Prion Diseases

Neurological Disorders: Course and Treatment: Second Edition

Volumn , Issue , 2003, Pages 707-720

  Knight, Richard ^a   Will, Bob ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649339872     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012125831-3/50249-5     Document Type: Chapter

References (65)

1. Adjou K.T., Demaimay R., Lasmézas C.I., Seman M., Deslys J.-P., Dormont D. Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Res. Virol. 1996, 147:213-218.
2. Braham J. Jakob-Creutzfeldt disease: treatment by Amantadine. BMJ 1971, 4:212-213.
3. Brandner S., Isenmann S., Raeber A., et al. Normal host prion protein necessary for scrapie-induced neurotoxicty. Nature 1996, 379:339-343.
4. Brimacombe D.B., Bennett A.D., Wusteman F.S., Gill A.C., Dann J.C., Bostock C.J. Characterization and polyanionbinding properties of purified recombinat prion protein. Biochem. J. 1999, 342:605-613.
5. Brown D.R. Prion protein-overexpressing cells show altered response to a neurotoxic prion protein peptide. J. Neurosci. Res. 1998, 54:331-340.
6. Brown D.R. Prion protein peptide neurotoxicity can be mediated by astrocytes. J. Neurochem. 1999, 73:1105-1113.
7. Brown D.R., Besinger A. Prion protein expression and superoxide dismutase activity. Biochem. J. 1998, 334:423-429.
8. Brown D.R., Qin K., Herms J.W., et al. The cellular prion protein binds copper in vivo. Nature 1997, 390:684.
9. Brown D.R., Mohn C.M. Astrocytic glutamate uptake and prion protein expression. Glia 1999, 25:282-292.
10. Brown D.R., Schmidt B., Kretzschmar H.A. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 1996, 380:345-347.
11. Brown D.R., Schmidt B., Kretzschmar H.A. Effects of copper on survival of prion protein knockout neurons and glia. J. Neurochem. 1998, 70:1686-1693.
12. Brown D.R., Wong B.-S., Hafiz F., Clive C., Haswell S.J., Jones I.M. Normal prion protein has an activity like that of superoxide dismutase. Biochem. J. 1999, 344:1-5.
13. Brown P., Preece M., Brandel J.-P., Saro T., McShane L., Zerr I., Fletcher A., Will R.G., Pocchiari M., Cashman N.R., d'Aignaux J.H., Cervenakova L., Fradkin J., Schonberger L.B., Collins S.J. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000, 55:1075-1081.
14. Brown P., Preece M.A., Will R.G. "Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992, 340:24-27.
15. Büeler H., Aguzzi A., Sailer A., et al. Mice devoid of PrP are resistant to scrapie. Cell 1993, 73:1339-1347.
16. Büeler H., Fischer M., Lang Y., Bluethmann H., Lipp H.P., DeArmond S.J., et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992, 356:577-582.
17. Colling S.B., Collinge J., Jefferys J.G. Hippocampal slices from prion protein null mice: disrupted Ca(2+)-activated K+ currents. Neurosci. Lett. 1996, 209(1):49-52.
18. Collinge J., Whittington M.A., Sidle K.C.L., et al. Prion protein is necessary for normal Synaptic function. Nature 1994, 370:295-297.
19. Cousens S., Smith P.G., Ward H., Everington D., Knight R.S.G., Zeidler M., Stewart G., Smith-Bathgate E.A.B., Macleod M.A., Mackenzie J., Will R.G. Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994-2000. Lancet 2001, 2001:1002-1007.
20. David A.S., Grant R., Ballantyne J.P. Uncusccessful treatment of Creutzfeldt-Jakob disease with acylovir. Lancet 1984, i:512-513.
21. Diringer H., Ehlers B. Chemoprophyaxis of scrapie in mice. J. Gen Virol. 1991, 72:457-460.
22. Ehlers B., Diringer H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J. Gen. Virol. 1984, 65:1325-1330.
23. Farquhar C.F., Dickinson A.G. Prolongation of scrapie incubation period by an injection of dextran 500 within the month before or after infection. J. Gen. Virol. 1986, 67:463-473.
24. Finkenstaedt M., Szudra A., Zerr I., Poser S., Hise J.H., Stoebner J.M., Weber T. MR imaging of Creutzfeldt-Jakob disease. Radiology 1996, 199:793-798.
25. Furlow T.W., Whitley R.J., Wilmes F.J. Repeated supression of Creutzfeldt-Jakob disease with vidarabine. Lancet 1982, ii:564-565.
26. Gambetti P., Petersen R.B., Parchi P., Chen S.G., Capellari S., Goldfarb L., Gabizon R., Montagna P., Lugaresi E., Piccardo P., Ghetti B. Inherited prion diseases. Prion Biology and Diseases 1999, 509-583. Cold Spring Harbour, New York. S.B. Prusiner (Ed.).
27. Green A.J.E., Thompson E.J., Stewart G.E., Zeidler M., Mackenzie J.M., Macleod M.A., Ironside J.W., Will R.G., Knight R.S.G. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. JNNP 2001, 2001:744-748.
28. Herms J.W., Kretzschmar H.A., Titz S., Kller B.U. Patch-clamp analysis of synaptic transmission to cerebellar Purkinje cells of prion protein knockout mice. Eur. J. Neurosci. 1995, 7:2508-2512.
29. Knight R. The relationship between new variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Vox Sanguinis 1999, 76:203-208.
30. Knight R. Therapeutic possibilities in CJD: patents 1996-1999. Exp. Opin. Ther. Patents. 2000, 10(1):49-57.
31. Korth C., May B.C.H., Cohen F.E., Prusiner S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA 2001, 98(17):9836-9841.
32. Sc)-specific epitope defined by a monoclonal antibody. Nature 1997, 390:74-77.
33. Kovanen J., Haltia M., Cantell K. Failure of interferon to modify Creutzfeldt-Jakob disease. B.M.J. 1980, 280:902-903.
34. Kunz B., Sandmeier E., Christe N.P. Neurotoxicity of prion peptide 106-126 not confirmed. FEBS. Lett. 1999, 458:65-68.
35. Lledo P.-M., Tremblay P., DeArmond S.J., Prusiner S.B., Nicoll R.A. Mice deficient for prion protein exhibit normal neuronal excitability and synaptic transmission in the hippocampus. Proc. Natl. Acad. Sci. USA 1996, 93:2403-2407.
36. Manson J.C., Clarke A.R., Hooper M.L., Aitchison L., McConnell I., Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol. Biol. 1994, 8:121-127.
37. Manuelidis L., Fritch W., Zaitsev I. Dapsone to delay symptoms in Creutzfeldt-Jakob disease. Lancet 1998, 352:456.
38. Masullo C., Macchi G., Xi Y.G., Pocchiari M. Failure to ameliorate Creutzfeldt-Jakob disease with Amphotericin B therapy. J. Infect. Dis. 1992, 165:784-785.
39. McKenzie D., Bartz J., Mirwald J., Olader D., Marsh R., Aiken J. Reversibility of scrapie inactivation is enhanced by copper. J. Biol. Chem. 1998, 273:255545-255547.
40. McKenzie D., Kaczkowski J., Marsh R., Aiken J. Amphotericin B delays both Scrapie agent replication and PrP-res accumulation early in infection. J. Virol. 1994, 68:7534-7536.
41. Moore R. Gene targeting studies at the mouse prion protein locus. PhD Thesis 1997, University of Edinburgh, Edinburgh.
42. Moore R.C., Lee I.Y., Silverman G.L., et al. Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. J. Mol. Biol. 1999, 292:797-817.
43. Palmer M.S., Collinge J. Prion diseases: an introduction. Prion Diseases 1997, 1-17. Oxford University Press Inc, New York. J. Collinge, M.S. Palmer (Eds.).
44. Pauly P.C., Harris D.A. Copper stimulates endocytosis of the prion protein. J. Biol. Chem. 1998, 273:33107-33110.
45. Pocchiari M., Salvatore M., Ladogana A., et al. Experimental drug treatment of scrapie: a pathogenetic basis for rationale therapeutics. Eur. J. Epidemiol. 1991, 7:556-561.
46. Prout K.A., Larner A.J. Emerging therapeutic possibilities in prion diseases: patents 1993-1998. Expert. Opin. Therap. Patents 1998, 8(9):1099-1108.
47. Prusiner S.B. An introduction to Prion biology and diseases. Prion Biology and Diseases 1999, 1-66. Cold Spring Harbour Laboratory Press, New York. S.B. Prusiner (Ed.).
48. Sakaguchi S., Katamine S., Nishida N., et al. Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. Nature 1996, 380:528-531.
49. Sanders W.L., Dunn T.L. Creutfeldt-Jakob disease treated with amantidine. A report of two cases. JNNP 1973, 36:581-584.
50. Steinhoff B.J., Racker s., Herrendorf G., Poser S., Grosche S., Zerr I., Kretzschmar H., Weber T. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch. Neurol. 1996, 53:162-165.
51. Tateishi J. Antibiotics and antivirals do not modify experimentally induced Creutzfeldt-Jakob disease in mice. JNNP 1981, 44:723-724.
52. Tobler I., Gauss S.E., Deboer T., et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 1996, 380(6575):639-642.
53. Tremblay P., Meiner Z., Galou M., et al. Doxycycline control of prion protein transgene expression modulates prion disease in mice. Proc. Natl. Acad. Sci. USA 1998, 13:12580-12585.
54. Westaway D., DeArmond S.J., Cayetano-Canlas J., et al. Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type proteins. Cell 1994, 76(1):117-129.
55. Will R.G., Alpers M.P., Dormont D., Schonberger L.B., Tateishi J. Infectious and sporadic prion diseases. Prion Biology and Diseases 1999, 465-507. Cold Spring Harbour Laboratory Press, New York. S.B. Prusiner (Ed.).
56. Will R.G., Ironside J.W., Zeidler M., Cousens S.N., Estibeiro K., Alperovitch A., Poser S., Pocchiari M., Hofman A., Smith P.G. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996, 347:921-925.
57. Will R.G., Kimberlin R.H. Creutzfeldt-Jakob disease and the risk from blood or blood products. Vox Sanguinis 1998, 75:178-180.
58. Will R.G., Zeidler M., Stewart G.E., Macleod M.A., Ironside J.W., Cousens S.N., Mackenzie J., Estibeiro K., Green A.J.E., Knight R.S.G. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann. Neurol. 2000, 47:575-582.
59. Windl O., Dempster M., Estibeiro J.P., Lathe R., De Silva R., Esmonde T., Will R., Springbett A., Campbell T.A., Sidle K.C.L., Palmer M.S., Collinge J. Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. Hum. Gene. 1996, 98:259-264.
60. World Health Organization WHO Manual for Strengthening Diagnosis and Surveillance of Creutzfeldt-Jakob Disease 1998, 1-75. Geneva.
61. Xi Y.G., Ingrosso L., Lagonda A., Masullo C., Pocchiari M. amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature 1992, 356:598-601.
62. Zeidler M., Sellar R.J., Collie D.A., Knight R., Stewart G., Macleod M.A., Ironside J.W., Cousens S., Colchester A.F.C., Hadley D.M., Will R.G. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000, 355:1412-1418.
63. Zerr I., Bodemer M., Gefeller O., Otto M., Poser S., Wiltfang J., Windl O., Kretzschmar H.A., Weber T. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann. Neurol. 1998, 43:32-40.
64. Zerr I., Brandel J.-P., Masullo C., Wientjens D., De Silva R., Zeidler M., Granieri E., Sampaolo S., van Duijn C., Delasnerie-Laupretre N., Will R., Poser S. European surveillance on Creutzfeldt-Jakob disease: A case-control study for medical risk factors. J. Clin. Epidimiol. 2000, 53:747-754.
65. Zerr I., Pocchiari M., Collins S., Brandel J.-P., de Pedro Cuesta J., Knight R.S., Bernheimer H., Cardone F., Delasnerie-Laupretre N., Cuadrado Corrales N., Ladogana A., Bodemer M., Fletcher A., Awan T., Ruiz Bremon A., Budka H., Laplanche J.-L., Will R.G., Poser S. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000, 55(6):811-815.